Keros Therapeutics, Inc. (KROS) P/E Ratio History
Historical price-to-earnings valuation from 2025 to 2025
Loading P/E history...
KROS Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 7, 2026, Keros Therapeutics, Inc. (KROS) trades at a price-to-earnings ratio of 5.1x, with a stock price of $11.78 and trailing twelve-month earnings per share of $2.30.
The current P/E is 79% below its 5-year average of 24.2x. Over the past five years, KROS's P/E has ranged from a low of 8.9x to a high of 53.4x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, KROS trades at a 77% discount to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 178.0x.
Relative to the broader market, KROS trades at a notable discount to the S&P 500 median P/E of 25.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our KROS DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
KROS P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $9B | 42.2 | -Best | +128% | |
| $6B | 8.6Lowest | -Best | +264%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
KROS Historical P/E Data (2025–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $20.36 | $2.30 | 8.9x | -63% |
| FY2025 Q3 | $15.82 | $1.54 | 10.3x | -58% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $13.35 | $0.25 | 53.4x | +121% |
Average P/E for displayed period: 24.2x
See KROS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs KROS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare KROS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonKROS — Frequently Asked Questions
Quick answers to the most common questions about buying KROS stock.
Is KROS stock overvalued or undervalued?
KROS trades at 5.1x P/E, below its 5-year average of 24.2x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does KROS's valuation compare to peers?
Keros Therapeutics, Inc. P/E of 5.1x compares to sector median of 22.1x. The discount suggests lower growth expectations or higher risk.
What is KROS's PEG ratio?
KROS PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2025-2025.